An official website of the United States government
Here's how you know
A .mil website belongs to an official U.S. Department of Defense organization in the United States.
A lock (lock ) or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

ArticleCS - Article View
NEWS | March 21, 2020

Navy Preventive Medicine Teams Embark Ships in 7th Fleet

By U.S. 7th Fleet Public Affairs Office

SOUTH CHINA SEA – Members of Navy Forward-Deployed Preventive Medicine Units (FDPMU) and Naval Medical Research Center (NMRC) embarked several 7th Fleet ships March 14 to help combat the risk of and provide laboratory batch testing for COVID-19 onboard the ships.

Teams are embarked on the amphibious assault ship USS America (LHA 6), the aircraft carrier USS Theodore Roosevelt (CVN 71), and the U.S. 7th Fleet flagship USS Blue Ridge (LCC 19) and have the ability to batch test Sailors onboard who present with influenza-like illness symptoms, instead of only sending samples to be tested ashore.

This capability provides early-warning surveillance for the medical teams to be able to identify if a COVID-19 case is onboard a ship, but does not individually diagnose Sailors. If a batch were to test positive for COVID-19, the medical teams would take additional measures, such as isolating the Sailors whose samples were in the batch, and depending on the Sailor’s symptoms, potentially medically evacuating them off the ship to a shore facility for testing.

To date, no cases of COVID-19 have been diagnosed aboard any U.S. 7th Fleet Navy vessel.

“The team here in 7th Fleet has taken COVID-19 seriously from the beginning and has many public health measures already in place,” said Capt. Christine Sears, U.S. 7th Fleet Surgeon. “The FDPMU and NMRC augmentation teams provide additional depth in our ability to combat this virus.”

Teams embarked the ships to provide at-sea testing and to ensure the U.S. 7th Fleet operating forces are ready to combat a possible outbreak while maintaining mission readiness. The teams provide additional capabilities in addition to the U.S. 7th Fleet’s isolation procedures.

The teams are comprised of a variety of specialized Navy Medicine personnel to ensure force health protection of the fleet, and may include: a microbiologist, medical laboratory technician, preventive medicine officer, preventive medicine technician.

“As a medical service corps microbiology officer, this embark gives us the chance to demonstrate some of our skillsets to the fleet, and what we bring to the fight,” said Lt. Cmdr. Rebecca Pavlicek, Blue Ridge COVID-19 testing team lead. “This capability allows us, the Navy, to protect mission readiness and protection of our Sailors.”

To ensuring force health protection of the fleet, other medical specialties or logistical components can be scaled up or down to meet mission specific requirements in the mitigation, health surveillance, and casualty prevention.

The 4-person team aboard America was the first to bring COVID-19 testing capability to a U.S. Navy ship.

“This is the most advanced laboratory capability that Navy Medicine has placed forward deployed,” said Cmdr. Brian Legendre, team lead and preventative medicine officer for the preventative medicine team aboard America.

“We can make force health protection decisions in real time, enhancing the health of the crew while minimizing any potential outbreak of COVID-19,” added Lt. Cmdr. Danett Bishop, team microbiologist.

The FDPMU teams aboard the USS America and the USS Blue Ridge are from Navy Environmental Preventative Medicine Unit Six based out of Pearl Harbor, Hawaii, and work to facilitate and educate using preventive medicine practices and provide additional laboratory capabilities. The team embarked with USS Theodore Roosevelt is assigned to the Naval Medical Research Center based in Silver Spring, Maryland.

Currently, the teams are only authorized to perform surveillance testing and not individual testing. This means that the results cannot be linked to a particular patient for diagnostics, but would enable the team to detect COVID-19’s presence on the ship based off of the results.

“Since we are performing surveillance testing, the results of COVID-19 present, or not present can help inform the force health protection posture and provide valuable insight for the senior medical officer and outbreak response team,” said Pavlicek.

The teams are equipped with two testing capabilities, including the BioFire Film Array and the Step One RT-PCR System. The BioFire Film Array will test for a dozen different respiratory diseases, while the Step One RT-PCR System allow for complex COVID-19 tests at sea, if necessary.

As the U.S. Navy's largest forward-deployed fleet, 7th Fleet operates roughly 50-70 ships and submarines and 140 aircraft with approximately 20,000 Sailors.


Google Translation Disclaimer

  • Google Translate, a third party service provided by Google, performs all translations directly and dynamically.
  • Commander, U.S. 7th Fleet, has no control over the features, functions, or performance of the Google Translate service.
  • The automated translations should not be considered exact and should be used only as an approximation of the original English language content.
  • This service is meant solely for the assistance of limited English-speaking users of the website.
  • Commander, U.S. 7th Fleet, does not warrant the accuracy, reliability, or timeliness of any information translated.
  • Some items cannot be translated, including but not limited to image buttons, drop down menus, graphics, photos, or portable document formats (pdfs).
  • Commander, U.S. 7th Fleet, does not directly endorse Google Translate or imply that it is the only language translation solution available to users.
  • All site visitors may choose to use similar tools for their translation needs. Any individuals or parties that use Commander, U.S. 7th Fleet, content in translated form, whether by Google Translate or by any other translation services, do so at their own risk.
  • IE users: Please note that Google Translate may not render correctly when using Internet Explorer. Users are advised to use MS Edge, Safari, Chrome, or Firefox browser to take full advantage of the Google Translate feature.
  • The official text of content on this site is the English version found on this website. If any questions arise related to the accuracy of the information contained in translated text, refer to the English version on this website, it is the official version.